quinta-feira, 12 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 15, 2026

Procter & Gamble (PG) Stock After Recent Pullback Is The Current Price Tag Justified

View original at finance.yahoo.com
Procter & Gamble (PG) Stock After Recent Pullback Is The Current Price Tag Justified Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The estimated intrinsic value of Procter & Gamble is approximately $186.75 per share based on discounted cash flow modeling

    60% confidence

  • The DCF model uses analyst-provided free cash flow estimates for the next few years, then extrapolates beyond that horizon

    60% confidence

  • Procter & Gamble scores 3 out of 6 on Simply Wall St's 6-point valuation checklist

    60% confidence

  • The DCF model output implies Procter & Gamble stock is 19.9% undervalued relative to its current share price of approximately $149.61

    60% confidence

  • Procter & Gamble's free cash flow is projected to reach approximately $21.3 billion by 2035 under the DCF model's assumptions

    60% confidence

  • Procter & Gamble is a large consumer staples stock that many investors watch closely when reassessing defensive holdings and income-focused positions

    60% confidence

Data points we hold from this source

Procter & Gamble · stock price149.61 USD
Procter & Gamble · margin2.1 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,565 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Procter & Gamble (PG) Stock After Recent Pullback Is The Current Price Tag Justified — Source | Via News | pt.VIA.NEWS